NextCell Pharma AB (OSTO:NXTCL) Capex-to-Revenue : 0.02 (As of Feb. 2024)

NextCell Pharma AB Capex-to-Revenue Chart

NextCell Pharma AB Annual Data
	Trend	Aug15	Aug16	Aug17	Aug18	Aug19	Aug20	Aug21	Aug22	Aug23
Capex-to-Revenue		Get a 7-Day Free Trial				0.22	0.22	0.19	1.36	0.41

NextCell Pharma AB Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Capex-to-Revenue	Get a 7-Day Free Trial															0.45	0.73	0.10	0.01	0.02

Competitive Comparison of NextCell Pharma AB's Capex-to-Revenue

For the Biotechnology subindustry, NextCell Pharma AB's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NextCell Pharma AB's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where NextCell Pharma AB's Capex-to-Revenue falls into.

NextCell Pharma AB Capex-to-Revenue Calculation

NextCell Pharma AB's Capex-to-Revenue for the fiscal year that ended in Aug. 2023 is calculated as

NextCell Pharma AB's Capex-to-Revenue for the quarter that ended in Feb. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB  (OSTO:NXTCL) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

NextCell Pharma AB Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCell Pharma AB (OSTO:NXTCL) Business Description